CDKN2A and osteoporosis: Targeting this TGF‐β‐oxidative‐stress‐cellular senescence pathway by inhibition of TGF‐β signaling, antioxidant treatment, or Cdkn2a inactivation can ameliorate the osteoporosis phenotype in GO.